Developed by Merz Pharmaceuticals, Memary is an N-methyl-D-aspartate (NMDA) receptor antagonist which has been approved by European EMEA in 2002 and by the US Food and Drug Administration in 2003.
The AD drug is currently marketed in 70 countries throughout the world.